Dupilumab's Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life

BACKGROUND: Dupilumab represents the first approved biological for severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). OBJECTIVE: Aim of this paper is to provide a multicentric real-life study about treatment with dupilumab for CRSwNP with a special focus on blood parameters and I...

Descripción completa

Detalles Bibliográficos
Autores principales: Loperfido, Antonella, Ciofalo, Andrea, Cavaliere, Carlo, Begvarfaj, Elona, Cascone, Francesca, Alfonzo, Giacomo, Cadeddu, Rosalba, Millarelli, Stefano, Bellocchi, Gianluca, Greco, Antonio, de Vincentiis, Marco, Masieri, Simonetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516700/
https://www.ncbi.nlm.nih.gov/pubmed/37745203
http://dx.doi.org/10.1155/2023/4027701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516700/
https://www.ncbi.nlm.nih.gov/pubmed/37745203
http://dx.doi.org/10.1155/2023/4027701

Ejemplares similares